Payment overview · 2025
General Payments
$128.75
8 reported records · 6 companies
Healthcare provider profile · identity verified
Heather Licke, MD
Allopathic & Osteopathic Physicians|Family Medicine · SAINT FRANCIS, KS · NPI 1093026429
Verified facts
What the public records show
CMS Open Payments records show Heather Licke, MD received $128.75 in general payments during 2025 across 8 reported records.
ABBVIE INC. accounted for 46.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIBERZI as an associated drug or biological on 11354 records involving 5020 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Viberzi by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $59.73 | 46.4% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.12 | 13.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.76 | 10.7% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $13.63 | 10.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $13.62 | 10.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $10.89 | 8.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $128.75 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $37.52 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $22.21 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.12 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.12 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.76 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $13.63 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $13.62 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $10.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 122 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 57 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
75 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
53 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VIBERZI open payments reported associated product |
CMS Open Payments — General Payments 11354 supporting records · 5020 recipient NPIs · example record 1201352948 |
Viberzi · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
57 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
63 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
91 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
122 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
69 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
91 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
85 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 929 | 153 |
| Atorvastatin Calcium | Atorvastatin Calcium | 687 | 124 |
| Omeprazole | Omeprazole | 662 | 98 |
| Lisinopril | Lisinopril | 655 | 103 |
| Eliquis | Apixaban | 508 | 59 |
| Furosemide | Furosemide | 500 | 92 |
| Pantoprazole Sodium | Pantoprazole Sodium | 379 | 61 |
| Amlodipine Besylate | Amlodipine Besylate | 367 | 81 |
| Potassium Chloride | Potassium Chloride | 359 | 62 |
| Montelukast Sodium | Montelukast Sodium | 328 | 48 |
| Metoprolol Succinate | Metoprolol Succinate | 321 | 59 |
| Gabapentin | Gabapentin | 305 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 298 | 52 |
| Simvastatin | Simvastatin | 286 | 51 |
| Losartan Potassium | Losartan Potassium | 281 | 57 |
| Trazodone Hcl | Trazodone Hcl | 246 | 44 |
| Famotidine | Famotidine | 235 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 225 | 31 |
| Oxycodone Hcl | Oxycodone Hcl | 222 | 34 |
| Carvedilol | Carvedilol | 207 | 37 |
| Sertraline Hcl | Sertraline Hcl | 199 | 32 |
| Gemtesa | Vibegron | 197 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 191 | 45 |
| Escitalopram Oxalate | Escitalopram Oxalate | 189 | 29 |
| Allopurinol | Allopurinol | 188 | 32 |
| Metformin Hcl | Metformin Hcl | 188 | 37 |
| Pregabalin | Pregabalin | 186 | 31 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 179 | 32 |
| Myrbetriq | Mirabegron | 174 | 20 |
| Xarelto | Rivaroxaban | 170 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 153 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 146 | 26 |
| Donepezil Hcl | Donepezil Hcl | 146 | 19 |
| Tramadol Hcl | Tramadol Hcl | 133 | 39 |
| Meloxicam | Meloxicam | 132 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 128 | 38 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 127 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 125 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 124 | 27 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 123 | 22 |
| Mounjaro | Tirzepatide | 122 | 14 |
| Alprazolam | Alprazolam | 120 | 21 |
| Spironolactone | Spironolactone | 107 | 20 |
| Warfarin Sodium | Warfarin Sodium | 103 | 13 |
| Celecoxib | Celecoxib | 97 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 97 | 15 |
| Lorazepam | Lorazepam | 94 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 94 | 16 |
| Bumetanide | Bumetanide | 93 | 16 |
| Jardiance | Empagliflozin | 91 | 14 |
| Ozempic | Semaglutide | 91 | 15 |
| Prednisone | Prednisone | 91 | 33 |
| Januvia | Sitagliptin Phosphate | 90 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 89 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 86 | 16 |
| Buspirone Hcl | Buspirone Hcl | 85 | 19 |
| Rybelsus | Semaglutide | 85 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 84 | 13 |
| Atenolol | Atenolol | 77 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 77 | suppressed |
| Linzess | Linaclotide | 75 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 74 | 15 |
| Trulicity | Dulaglutide | 69 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 68 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 68 | 13 |
| Risperidone | Risperidone | 67 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 66 | 17 |
| Metolazone | Metolazone | 66 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 65 | 13 |
| Cephalexin | Cephalexin | 64 | 20 |
| Fluconazole | Fluconazole | 64 | 23 |
| Glipizide | Glipizide | 64 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 63 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 62 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 62 | 13 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 61 | 48 |
| Finasteride | Finasteride | 60 | suppressed |
| Estradiol | Estradiol | 59 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 57 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 57 | suppressed |
| Vraylar | Cariprazine Hcl | 57 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 56 | 12 |
| Memantine Hcl | Memantine Hcl | 54 | 12 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 53 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 53 | suppressed |
| Synthroid | Levothyroxine Sodium | 53 | 13 |
| Spiriva Respimat | Tiotropium Bromide | 51 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 50 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 50 | suppressed |
| Fentanyl | Fentanyl | 49 | suppressed |
| Novolog Flexpen | Insulin Aspart | 49 | 11 |
| Olanzapine | Olanzapine | 48 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 48 | suppressed |
| Clonazepam | Clonazepam | 47 | suppressed |
| Novolog | Insulin Aspart | 47 | suppressed |
| Colchicine | Colchicine | 44 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 44 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 44 | 15 |
| Topiramate | Topiramate | 43 | suppressed |
| Baclofen | Baclofen | 42 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 41 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 40 | 40 |
| Digoxin | Digoxin | 40 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 40 | suppressed |
| Sucralfate | Sucralfate | 40 | suppressed |
| Calcitriol | Calcitriol | 39 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 39 | suppressed |
| Anastrozole | Anastrozole | 38 | suppressed |
| Bupropion Xl | Bupropion Hcl | 38 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 38 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 38 | 17 |
| Terazosin Hcl | Terazosin Hcl | 38 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 38 | 12 |
| Oxycontin | Oxycodone Hcl | 37 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | suppressed |
| Azithromycin | Azithromycin | 36 | 26 |
| Dicyclomine Hcl | Dicyclomine Hcl | 36 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 36 | suppressed |
| Mirtazapine | Mirtazapine | 36 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 36 | suppressed |
| Np Thyroid | Thyroid,pork | 35 | suppressed |
| Aripiprazole | Aripiprazole | 34 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 34 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 34 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 34 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 15 |
| Latanoprost | Latanoprost | 34 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 20 |
| Naproxen | Naproxen | 33 | suppressed |
| Nystatin | Nystatin | 33 | 18 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 33 | 22 |
| Combigan | Brimonidine Tartrate/Timolol | 32 | suppressed |
| Diazepam | Diazepam | 32 | suppressed |
| Levetiracetam | Levetiracetam | 32 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 31 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 31 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 31 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 30 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 30 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 20 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 29 | 29 |
| Febuxostat | Febuxostat | 29 | suppressed |
| Ibuprofen | Ibuprofen | 29 | suppressed |
| Methylprednisolone | Methylprednisolone | 29 | 25 |
| Carisoprodol | Carisoprodol | 28 | suppressed |
| Glipizide Er | Glipizide | 28 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 28 | suppressed |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Movantik | Naloxegol Oxalate | 27 | suppressed |
| Gemfibrozil | Gemfibrozil | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Tradjenta | Linagliptin | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Lansoprazole | Lansoprazole | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 24 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Pulmicort Flexhaler | Budesonide | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 12 |
| Budesonide | Budesonide | 22 | suppressed |
| Viberzi | Eluxadoline | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 21 | suppressed |
| Creon | Lipase/Protease/Amylase | 20 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 20 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 19 | suppressed |
| Belsomra | Suvorexant | 18 | suppressed |
| Dulera | Mometasone/Formoterol | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Repatha Sureclick | Evolocumab | 18 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | 11 |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Humalog | Insulin Lispro | 17 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 13 |
| Norethindron-Ethinyl Estradiol | Norethindrone Ac/Eth Estradiol | 16 | suppressed |
| Phenobarbital | Phenobarbital | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 16 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Methadone Hcl | Methadone Hcl | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 14 | suppressed |
| Glyburide | Glyburide | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 14 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 13 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Xtampza Er | Oxycodone Myristate | 13 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 12 | 12 |
| Atomoxetine Hcl | Atomoxetine Hcl | 12 | suppressed |
| Auvelity | Dextromethorphan Hbr/Bupropion | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Caplyta | Lumateperone Tosylate | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Prevalite | Cholestyramine | 12 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Cefadroxil | Cefadroxil | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Roflumilast | Roflumilast | 11 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $128.75 · 8 records | ABBVIE INC. | AIRSUPRA, JOURNAVX, MOUNJARO, QULIPTA, VOQUEZNA, VRAYLAR, Wegovy, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error